# Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

> **NCT00691470** · PHASE2,PHASE3 · UNKNOWN · sponsor: **ARYx Therapeutics** · enrollment: 600 (estimated)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter
- Venous Thromboembolic Disease
- Myocardial Infarction
- Cardiomyopathy

## Interventions

- **DRUG:** ATI-5923
- **DRUG:** Coumadin (warfarin)

## Key facts

- **NCT ID:** NCT00691470
- **Lead sponsor:** ARYx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2010-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691470, "Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00691470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*